CBL-514 in Research: What the Published Clinical Studies Report

CBL-514 is an investigational small-molecule injectable developed by Caliway Biopharmaceuticals, based in New Taipei City, Taiwan. It is studied for reducing localised subcutaneous fat, and the clinical papers describe it as a lipolysis agent that induces adipocyte apoptosis, meaning programmed death of fat cells in the treated area. It is not an approved drug, and it is not a peptide.

This article summarises what the peer-reviewed literature and the public trial registry say about it, so that researchers can see where the evidence is solid and where it is thin. Everything below is reported from the cited sources; QSC has not run any of these studies.

What the studies say it does

The clinical papers describe a local effect: after injection into the fat layer, adipocytes in that area undergo apoptosis, and the fat volume of the treated region falls over the following weeks. The 2026 Phase 2b paper calls it "a small-molecule injectable lipolysis agent that induces adipocyte apoptosis" and notes that earlier Phase 2 work found reductions in subcutaneous fat measured by ultrasound, with no observed necrosis or nerve injury.

The molecular detail is thinner than the clinical detail. The developer has stated that its preclinical work shows CBL-514 raising the apoptosis mediators caspase 3 and the Bax/Bcl-2 ratio, but that is a company statement. A PubMed search for "CBL-514" on 29 October 2026 returned seven records, and none of them is a dedicated mechanism study.

The clinical programme at a glance

ClinicalTrials.gov lists sixteen CBL-514 studies: a Phase 1 safety study in healthy volunteers that started in 2018, a pharmacokinetic study, a series of Phase 2 studies in abdominal and other subcutaneous fat, Phase 2 studies in cellulite and in lipomas associated with Dercum's disease, and Phase 3 studies that are recruiting or planned. Most of the Phase 1 and Phase 2 studies are listed as completed, while the Phase 3 studies are recruiting or not yet recruiting.

Phase IIa dose-ranging study (2022)

Goodman and colleagues reported an open-label, randomly allocated Phase IIa study of several unit doses given over a six-week treatment period, with follow-up at four and eight weeks. There was no placebo arm; effects were measured against each participant's baseline. The higher unit doses significantly reduced abdominal fat volume and thickness, and the highest dose tested reduced abdominal fat volume by 24.96%. The authors concluded the doses tested were safe and well tolerated.

Placebo-controlled Phase II study (2025)

Gold and colleagues randomised 76 participants 2:1 to CBL-514 or placebo in a single-blind, placebo-controlled trial, with subcutaneous fat measured by ultrasound. Eight weeks after the final treatment, 69.6% of the CBL-514 group had lost at least 150 mL of subcutaneous fat compared with none in the placebo group, and 60.9% of the CBL-514 group reached a loss of at least 200 mL. Among the participants who lost at least 150 mL, 42.9% (12 of 28) reached that point after a single treatment. The most common adverse events were injection-site reactions, mild to moderate in severity.

Phase 2b study (2026)

Lorenc and colleagues reported a randomised, single-blind, placebo-controlled Phase 2b trial in 108 adults with moderate to severe abdominal subcutaneous fat. The primary outcome was the share of participants with at least a one-grade improvement on a clinician-reported abdominal fat rating scale at 12 weeks: 76.7% (23 of 30) in the CBL-514 group against 18.9% (7 of 37) on placebo. On the participant-reported version of the scale the figures were 76.7% against 19.4% (7 of 36). On MRI, the mean abdominal fat volume fell by 152.9 mL from baseline, a mean change of -20.3%, both significantly greater than placebo. The authors described CBL-514 as well tolerated, with mainly mild, transient injection-site reactions.

One detail worth noticing: the groups analysed for the main outcome (30 and 37 participants) are smaller than the 108 who were randomised, and the abstract does not explain the gap. A reader who needs to rely on these numbers should check the full paper for how the analysis populations were defined.

How to read this evidence

Several limits apply. The studies were designed and funded by the developer, and Caliway-affiliated authors appear on the Phase IIa and Phase 2b papers. The placebo-controlled trials were single-blind. Follow-up was short, eight to twelve weeks after the last treatment. The endpoints are fat volume, thickness and rating scales for an aesthetic outcome, not long-term outcomes. We found no independent replication. A 2026 systematic review of injectable lipolytic agents included CBL-514 among emerging agents, but its abstract pools safety across all agents and gives no CBL-514-specific figures.

What this does and does not mean for research-grade material

None of these studies used the material QSC supplies. The trials used the sponsor's own injectable formulation, given under clinical supervision, and their results say nothing about research-grade powder. QSC lists CBL-514 in 5 mg, 10 mg and 20 mg vials as lyophilized powder, strictly for laboratory research. It is not approved for human or veterinary use, and this article is not medical advice or a dosing recommendation.

For handling questions, including why peptide reconstitution habits do not carry over to a small molecule, see our companion article on small molecules versus peptides in the lab.

Sources

Lorenc ZP et al. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment. Aesthetic Surgery Journal, 2026 (online ahead of print, 20 May 2026). doi:10.1093/asj/sjag092. PMID 42159040.

Gold M et al. Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study. Aesthetic Surgery Journal, 2025;45(6):611-620. doi:10.1093/asj/sjaf032. PMID 40037659.

Goodman GJ et al. Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction. Aesthetic Surgery Journal, 2022;42(11):NP662-NP674. doi:10.1093/asj/sjac162. PMID 35709509.

Carrion K et al. A Systematic Review of Injectable Lipolytic Agents for Nonsurgical Fat Reduction. Plastic and Reconstructive Surgery, 2026;158(3):414-423. doi:10.1097/PRS.0000000000012648. PMID 41296813.

ClinicalTrials.gov, search term "CBL-514", accessed 29 October 2026. Caliway Biopharmaceuticals press release of 11 December 2024 (company-reported mechanism statement).